Atlas Trials

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Clinical trial NCT07143045 · RECRUITING

Trial details

NCT number
NCT07143045
Sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Status
RECRUITING
Study type
OBSERVATIONAL
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Start date
2025-12-29
Primary completion
2031-05-01
Enrollment
800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.